Proactive Investors
11 Jun 2026, 10:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
5 claims · each scored for market impact
Poolbeg Pharma PLC has activated the first clinical site for its POLB 001 TOPICAL trial and entered the patient recruitment phase. — Moving from preclinical to patient recruitment is a major de-risking milestone for a biotech company's lead asset.
+0.60CelLBxHealth PLC is in advanced talks with one of the largest private US healthcare providers to deploy its Parsortix cancer diagnostic platform. — Securing a partnership with a major US provider represents a significant potential leap in commercialization and revenue scale.
+0.50Poolbeg Pharma expects to release interim data for its POLB 001 program in summer 2026. — Provides a specific catalyst date that will likely drive significant price volatility based on the results.
+0.40Continue reading
6 related stories
CelLBxHealth PLC guided for 2026 revenues of at least £2.1 million, representing a 50% increase. — Positive growth guidance indicates improving fundamental financial performance.
+0.30Preclinical data for POLB 001 suggests potential efficacy in treating acute myeloid leukaemia (AML) in addition to its current focus. — Expanding the potential total addressable market (TAM) for the drug candidate increases the asset's long-term value.
+0.20Which stocks this story touches
The company is in advanced talks with a major US healthcare provider and guided for a 50% increase in annual revenues.
The company activated the first clinical site for its lead cancer immunotherapy programme and presented positive preclinical data.
Johnson & Johnson is mentioned only as a supplier of a drug for a clinical trial, which is not materially impactful to its business.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
PRNewsWire
10h ago
